1700-P: Weight Reduction Is Associated with Improved Quality of Life in Participants with Obesity or Overweight and Type 2 Diabetes—Results from Phase 3 SURMOUNT-2 Trial

Introduction & Objective: Tirzepatide is a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist approved in the US for treatment of type 2 diabetes and obesity. In the phase 3, randomized, double-blind, placebo (PBO)-controlled SURMOUNT-2 (NCT04657003) trial, tirzepatide-treated adults showed substantial weight reduction vs PBO. This post-hoc analysis assessed the association between achieving weight reduction targets and improvements in health-related quality of life (HRQoL).

Methods: HRQoL was assessed at baseline and week (W) 72 or early treatment discontinuation using 36-Item Short Form Health Survey, Version2 (SF-36v2), Impact of Weight on Quality of Life-Lite-Clinical Trials (IWQOL-Lite-CT), and EQ-5D-5L with higher scores representing better HRQoL. Mean changes from baseline to W72 were summarized by weight reduction targets (≥5%, ≥10%, ≥15%, ≥20%) in pooled tirzepatide-treated adults with last observed post-baseline value carried forward.

Results: At W72, adults with weight reduction showed improvements from baseline in all domains of SF-36v2 including Physical Functioning (norm-based) (≥5%, 3.78; ≥10%, 3.95; ≥15%, 4.74; ≥20%, 4.63) and Mental Health (norm-based) (≥5%, 1.65; ≥10%, 1.75; ≥15%, 2.34; ≥20%, 2.63). Adults who achieved most higher weight targets showed greater improvements from baseline in IWQOL-Lite-CT total score (≥5%, 14.68; ≥10%, 15.45; ≥15%, 18.53; ≥20%, 20.10), and Physical and Psychosocial composite scores. Greater improvement from baseline in EQ-5D VAS scores was observed in adults meeting greater weight reduction targets (≥5%, 9.75; ≥10%, 10.60; ≥15%, 12.33; ≥20%, 12.67).

Conclusion: Weight reduction in tirzepatide-treated adults was associated with improvement in all HRQoL domains, including physical function and mental health. Adults who lost the most weight generally showed the greatest HRQoL improvements.